enGene (NASDAQ:ENGN) Coverage Initiated at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of enGene (NASDAQ:ENGN) in a research note released on Monday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $30.00 price target on the stock.

ENGN has been the topic of several other research reports. UBS Group began coverage on shares of enGene in a report on Thursday, March 28th. They set a buy rating and a $37.00 price objective on the stock. Leerink Partnrs reaffirmed an outperform rating on shares of enGene in a research note on Tuesday, February 20th. Morgan Stanley began coverage on shares of enGene in a research note on Friday, March 8th. They issued an overweight rating and a $40.00 target price on the stock. Guggenheim began coverage on shares of enGene in a research note on Monday, April 15th. They set a buy rating and a $34.00 price objective on the stock. Finally, SVB Leerink started coverage on enGene in a report on Tuesday, February 20th. They issued an outperform rating and a $31.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus price target of $34.40.

enGene Stock Performance

NASDAQ:ENGN opened at $14.72 on Monday. The company has a 50 day moving average price of $16.21. enGene has a 12 month low of $6.69 and a 12 month high of $43.00.

Insiders Place Their Bets

In other news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $15.00, for a total value of $717,810.00. Following the transaction, the insider now directly owns 3,036,153 shares of the company’s stock, valued at $45,542,295. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Hedge Funds Weigh In On enGene

A number of large investors have recently made changes to their positions in the company. Vivo Capital LLC bought a new stake in enGene in the 4th quarter valued at $6,264,000. Omega Fund Management LLC acquired a new stake in shares of enGene during the fourth quarter worth $10,441,000. BVF Inc. IL bought a new stake in shares of enGene in the fourth quarter valued at about $20,777,000. Finally, Fcpm Iii Services B.V. acquired a new position in shares of enGene in the fourth quarter valued at about $80,097,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.